Literature DB >> 19427498

Hypertension and cardiac failure in its various forms.

Krishna K Gaddam1, Anil Verma, Mark Thompson, Rohit Amin, Hector Ventura.   

Abstract

Hypertension clearly increases the risk of systolic or diastolic heart failure. With aging population and advancements in treatment of cardiovascular diseases, the prevalence of heart failure is ever-increasing and is a principal cause of cardiovascular morbidity and mortality. Treating hypertension has been shown to decrease the risk of development of heart failure and hence underscores the early recognition and treatment of hypertension and hypertensive heart disease. Antihypertensive treatment with drugs from all classes except direct vasodilators is effective in reversing LVH and preventing heart failure. Also, all of the major classes of antihypertensive drugs, particularly beta-blockers and RAS antagonists, with the exception of calcium antagonists, have been shown to improve survival in patients who have LV systolic dysfunction. However, phenotyping and identifying the pathophysiology and appropriate treatments for patients who have diastolic dysfunction and heart failure with preserved ejection fraction has been a daunting task. At this time, treatment of these patients is largely empiric, focusing on BP control, and treating or avoiding intravascular volume overload.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427498     DOI: 10.1016/j.mcna.2009.02.005

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  8 in total

1.  Aldosterone receptor antagonists: effective but often forgotten.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

2.  Associations of LV hypertrophy with prevalent and incident valve calcification: Multi-Ethnic Study of Atherosclerosis.

Authors:  Sammy Elmariah; Joseph A C Delaney; David A Bluemke; Matthew J Budoff; Kevin D O'Brien; Valentin Fuster; Richard A Kronmal; Jonathan L Halperin
Journal:  JACC Cardiovasc Imaging       Date:  2012-08

3.  Angiotensin II-induced upregulation of AT(1) receptor expression: sequential activation of NF-kappaB and Elk-1 in neurons.

Authors:  Amit K Mitra; Lie Gao; Irving H Zucker
Journal:  Am J Physiol Cell Physiol       Date:  2010-06-16       Impact factor: 4.249

4.  Junb regulates arterial contraction capacity, cellular contractility, and motility via its target Myl9 in mice.

Authors:  Alexander H Licht; Tobias Nübel; Anja Feldner; Nathalie Jurisch-Yaksi; Marco Marcello; Elena Demicheva; Jun-Hao Hu; Bettina Hartenstein; Hellmut G Augustin; Markus Hecker; Peter Angel; Thomas Korff; Marina Schorpp-Kistner
Journal:  J Clin Invest       Date:  2010-06-14       Impact factor: 14.808

5.  The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action.

Authors:  Hyoung Kyu Kim; Jae Boum Youm; Sung Ryul Lee; Se Eun Lim; Sun-Young Lee; Tae Hee Ko; Le Thanh Long; Bernd Nilius; Du Nam Won; Jung-Hyun Noh; Kyung Soo Ko; Byoung Doo Rhee; Nari Kim; Jin Han
Journal:  Pflugers Arch       Date:  2012-10-17       Impact factor: 3.657

6.  Short‑term vagus nerve stimulation reduces myocardial apoptosis by downregulating microRNA‑205 in rats with chronic heart failure.

Authors:  Yanhua Xuan; Shuangshuang Liu; Yan Li; Jing Dong; Jiaying Luo; Tao Liu; Yuanzhe Jin; Zhijun Sun
Journal:  Mol Med Rep       Date:  2017-08-23       Impact factor: 2.952

7.  Perceived barriers and enablers influencing health extension workers toward home-based hypertension screening in rural northwest Ethiopia: interpretive descriptive study.

Authors:  Destaw Fetene Teshome; Shitaye Alemu Balcha; Tadesse Awoke Ayele; Asmamaw Atnafu; Mekonnen Sisay; Marye Getnet Asfaw; Getnet Mitike; Kassahun Alemu Gelaye
Journal:  BMC Health Serv Res       Date:  2022-09-13       Impact factor: 2.908

8.  Changes in Adherence to Non-Pharmacological Guidelines for Hypertension.

Authors:  Kyong Park; Sukyung Cho; Julie K Bower
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.